Semaglutide vs Tirzepatide: Which Is Better for Weight Loss?

The GLP-1 Revolution in Weight Management

Semaglutide and tirzepatide represent a paradigm shift in weight management pharmacology. Both belong to the incretin-based therapy class but differ in their receptor targets, which translates to differences in efficacy, side effect profiles, and dosing protocols. Understanding these differences helps researchers and clinicians make informed decisions.

Mechanism of Action: Single vs Dual Agonism

Semaglutide: GLP-1 Receptor Agonist

Semaglutide is a selective GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the natural incretin hormone GLP-1, which is released after eating. Its effects include:

• Slowing gastric emptying, which increases satiety and reduces food intake
• Stimulating insulin secretion in a glucose-dependent manner
• Suppressing glucagon release, reducing hepatic glucose output
• Acting on hypothalamic appetite centers to reduce hunger signaling

Tirzepatide: Dual GIP/GLP-1 Receptor Agonist

Tirzepatide targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual mechanism provides:

• All the GLP-1 effects listed above for semaglutide
• GIP-mediated enhancement of insulin secretion
• Potential direct effects on adipose tissue metabolism through GIP receptors
• Possibly greater impact on lipid metabolism and triglyceride levels

The dual agonism is thought to explain tirzepatide's superior weight loss results in clinical trials, as the two pathways create additive or synergistic effects on appetite suppression and metabolic function.

Clinical Trial Results: Head-to-Head Data

Semaglutide: STEP Trials

The STEP (Semaglutide Treatment Effect in People with obesity) trial program provided the landmark data for semaglutide 2.4 mg weekly:

• STEP 1: 14.9% average body weight reduction at 68 weeks vs 2.4% with placebo
• STEP 2: In patients with type 2 diabetes, 9.6% weight loss at 68 weeks
• STEP 3: Combined with intensive behavioral therapy, 16% weight loss
• STEP 5: Long-term (104 weeks) data showed sustained 15.2% weight loss

Tirzepatide: SURMOUNT Trials

The SURMOUNT trial program evaluated tirzepatide at multiple dose levels:

• SURMOUNT-1: At the 15 mg dose, participants achieved 22.5% average body weight reduction at 72 weeks, with 36.2% of participants losing 25% or more of their body weight
• SURMOUNT-2: In patients with type 2 diabetes, 14.7% weight loss at the 15 mg dose
• SURMOUNT-3: Combined with intensive lifestyle intervention, 26.6% weight loss

Dosing Protocols and Peptide Calculator Settings

Semaglutide Titration

The standard semaglutide dose escalation for weight management:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1.0 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance dose)

Tirzepatide Titration

The standard tirzepatide dose escalation:

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5.0 mg once weekly
• Weeks 9-12: 7.5 mg once weekly (optional intermediate step)
• Weeks 13-16: 10 mg once weekly
• Week 17 onward: 10-15 mg once weekly (based on response)

Use the Peptide Calculator Plus semaglutide and tirzepatide calculators to determine exact syringe units at each dose level based on your specific vial strength and reconstitution volume.

Side Effect Comparison

Both peptides share similar gastrointestinal side effects, which are the most common reason for discontinuation:

Notably, side effects for both drugs tend to be most pronounced during dose titration and often improve with continued use.

Cost and Accessibility Considerations

Both semaglutide (branded as Wegovy for weight loss) and tirzepatide (branded as Zepbound) carry significant costs when obtained through pharmacies. Research-grade versions of both peptides are available from peptide suppliers, though quality and purity can vary. Always verify third-party lab testing (Certificate of Analysis) for any research peptide.

Which Should You Research?

The choice between semaglutide and tirzepatide depends on several factors:

• Maximum weight loss potential: Tirzepatide has demonstrated greater average weight loss in clinical trials
• Established long-term data: Semaglutide has more published long-term safety and efficacy data
• GI tolerability: Individual responses vary, but tirzepatide may cause fewer GI issues at comparable efficacy levels
• Availability and cost: Semaglutide is more widely available in both branded and research forms

Using the Peptide Calculator for GLP-1 Peptides

Both semaglutide and tirzepatide use milligram-level dosing, which differs from many other peptides that use microgram doses. The Peptide Calculator Plus handles both scales accurately. Simply select your peptide, enter your vial strength and reconstitution volume, and the calculator will show you the exact volume and syringe units to draw for any dose in the titration schedule.